Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma

Leukemia Research

Volumn 35, Issue 12, 2011, Pages 1637-1643

  Evans, Robert P ^a   Dueck, Greg ^a   Sidhu, Roger ^a   Ghosh, Sunita ^a   Toman, Inka ^a   Loree, Jonathan ^a   Bahlis, Nizar ^a   Klimowicz, Alexander C ^a   Fung, Joyce ^a   Jung, Michelle ^a   Lai, Raymond ^a   Pilarski, Linda M ^a   Belch, Andrew R ^a   Reiman, Tony ^a  

^a SAINT JOHN REGIONAL HOSPITAL   (Canada)

Author keywords

Multiple myeloma; Novel therapeutics; PLK1; Polo like kinase 1

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; BORTEZOMIB; DEXAMETHASONE; MELPHALAN; POLO LIKE KINASE 1; SYNDECAN 1;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CANCER SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RETROSPECTIVE STUDIES; SMALL MOLECULE LIBRARIES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80055105318     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.07.016     Document Type: Article

References (27)

1. Kyle R.A., Rajkumar S.V. Multiple myeloma. N Engl J Med 2004, 351:1860-1873.
2. Keats J.J., Reiman T., Maxwell C.A., Taylor B.J., Larratt L.M., Mant M.J., et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003, 101:1520-1529.
3. Maxwell C.A., Keats J.J., Belch A.R., Pilarski L.M., Reiman T. Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Res 2005, 65:850-860.
4. Chng W.J., Ahmann G.J., Henderson K., Santana-Davila R., Greipp P.R., Gertz M.A., et al. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 2006, 107:3669-3675.
5. Fenton B., Glover D.M. A conserved mitotic kinase active at late anaphase-telophase in syncytial Drosophila embryos. Nature 1993, 363:637-640.
6. Glover D.M., Hagan I.M., Tavares A.A. Polo-like kinases: a team that plays throughout mitosis. Genes Dev 1998, 12:3777-3787.
7. Clay F.J., McEwen S.J., Bertoncello I., Wilks A.F., Dunn A.R. Identification and cloning of a protein kinase-encoding mouse gene, Plk, related to the polo gene of Drosophila. Proc Natl Acad Sci USA 1993, 90:4882-4886.
8. Holtrich U., Wolf G., Bräuninger A., Karn T., Böhme B., Rübsamen-Waigmann H., et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 1994, 91:1736-1740.
9. Lake R.J., Jelinek W.R. Cell cycle- and terminal differentiation-associated regulation of the mouse mRNA encoding a conserved mitotic protein kinase. Mol Cell Biol 1993, 13:7793-7801.
10. Lenart P., Petronczki M., Steegmaier M., Di Fiore B., Lipp J.J., Hoffmann M., et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007, 17:304-315.
11. Smith M.R., Wilson M.L., Hamanaka R., Chase D., Kung H., Longo D.L., et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997, 234:397-405.
12. Eckerdt F., Yuan J., Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005, 24:267-276.
13. Mross K., Steinbild S., Frost A., Hedborn S., Rentschler J., Kaiser R., et al. A Phase I single dose escalation study of the Polo-like kinase 1 (Plk1) inhibitor BI 2536 in patients with advanced solid tumors. Clin Cancer Res 2005, 11:9032.
14. Mross K., Frost A., Steinbild S., Hedbom S., Rentschler J., Kaiser R., et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008, 26:5511-5517.
15. Pawel Von J., Reck M., Digel W., Kortsik C., Thomas M., Frickhofen N., et al. Randomized phase II trial of two dosing schedules of BI 2536, a novel Plk-1 inhibitor, in patients with relapsed advanced or metastatic non-small-cell lung cancer (NSCLC). ASCO Meeting Abstracts 2008, p. 8030.
16. Olmos D., Barker D., Sharma R., Brunetto A.T., Yap T.A., Taegtmeyer A.B., et al. Phase I study of GSK461364, a specific and competitive Polo-like Kinase 1 (PLK1) inhibitor in patients with advanced solid malignancies. Clin Cancer Res 2011, (April).
17. Evans R.P., Naber C., Steffler T., Checkland T., Maxwell C.A., Keats J.J., et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2008, 140:295-302.
18. Evans R., Naber C., Steffler T., Checkland T., Keats J., Maxwell C., et al. Kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma 2008, 49:559-569.
19. Kyle R. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2008.
20. Engelhardt M., Kleber M., Udi J., Wäsch R., Spencer A., Patriarca F., et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 2010, 51:1424-1443.
21. Toman I., Loree J., Klimowicz A.C., Bahlis N., Lai R., Belch A., et al. Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics. Leuk Lymphoma 2011, 52:659-667.
22. Camp R.L., Chung G.G., Rimm D.L. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002, 8:1323-1327.
23. Keen N., Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004, 4:927-936.
24. Nigg E.A. Centrosome aberrations: cause or consequence of cancer progression?. Nat Rev Cancer 2002, 2:815-825.
25. Maxwell C.A., Rasmussen E., Zhan F., Keats J.J., Adamia S., Strachan E., et al. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood 2004, 104:1151-1158.
26. Chng W.J., Fonseca R. Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics. Clin Lymphoma Myeloma 2005, 6:200-207.
27. Strebhardt K., Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006, 6:321-330.